{
  "ticker": "ILA",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02967691",
  "id": "02967691",
  "pages": 18,
  "price_sensitive": false,
  "date": "20250709",
  "time": "0922",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250709/pdf/06lmnjf0w2f7pv.pdf",
  "summary": "### **Material Information Summary**  \n\n- **Galidesivir Acquisition Terms**:  \n  - Upfront payment: **$550k USD** (including $50k option fee)  \n  - **$500k USD** upon Phase 2 trial completion**  \n  - **$1M USD** upon FDA approval (or **$1.5M USD** if approved via Animal Rule with no Phase 2)  \n  - **5\u201310% tiered royalties** on net sales; **25% share of Priority Review Voucher (PRV)** proceeds (potential **$225M AUD per PRV**)  \n\n- **Regulatory Pathway**:  \n  - Targeting **Animal Rule** (potential FDA approval based on animal studies + one additional Marburg trial)  \n  - Aiming to complete required **non-human primate (NHP) study within 12 months**  \n\n- **Financial/Corporate**:  \n  - **Cash balance (31 March 2024)**: **$4.82M AUD**  \n  - **May 2025 capital raise**: **$3.6M AUD**  \n  - **Market cap (7 July 2025)**: **$34.24M AUD**  \n\n- **Key Catalysts**:  \n  - Finalizing **FDA consultations** on Animal Rule eligibility  \n  - Preparations for **Marburg NHP trial**  \n\n*No capital raising, trading halt, or quarterly financials disclosed. Forward-looking statements not material for immediate trading.*",
  "usage": {
    "prompt_tokens": 4519,
    "completion_tokens": 307,
    "total_tokens": 4826,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-08T23:34:19.916286"
}